The focus on TASK-1 inhibition exemplifies a targeted approach in AF management aimed at molecular modulation of atrial ion channel activity, marking a significant step forward in AF pharmacotherapy [4]. This evidence concerns the gene KCNK3 and atrial fibrillation.